Literature DB >> 9434686

Experience with living-donor lobar transplantation for indications other than cystic fibrosis.

V A Starnes1, M L Barr, F A Schenkel, M V Horn, R G Cohen, J A Hagen, W J Wells.   

Abstract

OBJECTIVE: Since development of a living donor bilateral lobar transplantation protocol for patients with cystic fibrosis, our indications have expanded to include recipients with other diagnoses.
METHODS: We report on our experience in eight patients with primary pulmonary hypertension, postchemotherapy pulmonary fibrosis, bronchopulmonary dysplasia, idiopathic pulmonary fibrosis, and obliterative bronchiolitis. The average age of the eight patients was 19.1 years (range 9 to 40). The mean preoperative carbon dioxide tension for the four patients who did not have primary pulmonary hypertension was 92 mm Hg (range 64 to 120 mm Hg), and the two patients with pulmonary fibrosis were intubated (one on high-frequency jet ventilation). Each recipient received a right lower lobe (n = 7) or middle lobe (n = 1) and a left lower lobe (n = 8) from a total of 16 donors representing various combinations of the recipient's family (n = 15) and an unrelated friend (n = 1).
RESULTS: With an average follow-up of 1 year the overall survival is 75%. For the five patients followed up for at least 1 year, mean forced vital capacity was 80.6%, forced expiratory volume in 1 second was 75.6%, mid-forced expiratory flow was 64%, and diffusing lung capacity corrected for alveolar volume was 73% of predicted. For those patients with primary pulmonary hypertension, preoperative hemodynamics revealed mean pressures as follows: blood pressure 84.8 mm Hg, right atrial pressure 7.8 mm Hg, pulmonary artery pressure 71.3 mm Hg, pulmonary capillary wedge pressure 9.5 mm Hg, cardiac index 2.9 L/min per square meter, and pulmonary vascular resistance index 22.8 Wood units. Postoperative hemodynamics revealed a mean blood pressure of 84.3 mm Hg, right atrial pressure of 2.7 mm Hg, pulmonary artery pressure of 16 mm Hg, pulmonary capillary wedge pressure of 7.3 mm Hg, cardiac index of 4.2 L/min per square meter, and pulmonary vascular resistance index of 1.9 Wood units.
CONCLUSIONS: Early results of living-donor bilateral lobar transplantation for diseases other than cystic fibrosis have resulted in satisfactory survival and pulmonary function. Additionally, patients with severe primary pulmonary hypertension have had dramatic normalization of their hemodynamics despite the limited amount of lung tissue transplanted. We believe that the data from this small cohort experience compares favorably with our larger series with cystic fibrosis and supports an expanded role for living-donor lobar transplantation in patients with alternate indications.

Entities:  

Mesh:

Year:  1997        PMID: 9434686     DOI: 10.1016/S0022-5223(97)70005-9

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  6 in total

Review 1.  History of lung transplantation.

Authors:  Federico Venuta; Dirk Van Raemdonck
Journal:  J Thorac Dis       Date:  2017-12       Impact factor: 2.895

2.  A 24-year-old woman with episodes of shortness of breath, cough and wheezing.

Authors:  Vivek Dhawan; Meena Kalluri
Journal:  CMAJ       Date:  2013-04-08       Impact factor: 8.262

Review 3.  Living-related lung transplantation.

Authors:  Hiroshi Date
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

4.  Effects of inhaled nitric oxide in a canine living-donor lobar lung transplant model.

Authors:  K Ueda; H Date; T Fujita; T Oto; I Nagahiro; M Aoe; A Andou; N Shimizu
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2000-11

5.  Morbidity and mortality of live lung donation: results from the RELIVE study.

Authors:  R D Yusen; B A Hong; E E Messersmith; B W Gillespie; B M Lopez; K L Brown; J Odim; R M Merion; M L Barr
Journal:  Am J Transplant       Date:  2014-08       Impact factor: 8.086

Review 6.  Current trends in thoracic surgery.

Authors:  Toyofumi F Chen-Yoshikawa; Takayuki Fukui; Shota Nakamura; Toshinari Ito; Yuka Kadomatsu; Hideki Tsubouchi; Harushi Ueno; Tomoshi Sugiyama; Masaki Goto; Shunsuke Mori; Naoki Ozeki; Shuhei Hakiri; Koji Kawaguchi
Journal:  Nagoya J Med Sci       Date:  2020-05       Impact factor: 1.131

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.